Genrix Bio signed a commercialization cooperation agreement for Weikang Duta monoclonal antibody injection and Sileweimi monoclonal antibody injection
I'm PortAI, I can summarize articles.
Genrix Bio has signed an exclusive cooperation agreement with CMS and RXILIENT for the exclusive rights to market Weikang Duta monoclonal injection and Sileweimi monoclonal injection. According to the agreement, Genrix Bio will receive an upfront payment and milestone payments, expected to total approximately RMB 510 million, while obtaining sales revenue in mainland China, the Asia-Pacific region, and North Africa. Tibet CMS and RXILIENT will respectively obtain exclusive commercialization rights for the aforementioned products in mainland China and other regions
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Zhitong The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments